ZAVRL FRANK 4

What Happened Frank Zavrl, a director of CervoMed, was granted an option to purchase 8,150 shares of the company's common stock. The Form 4 records the award as a derivative acquisition (code A) with an acquisition amount shown as $0.00; this reflects the grant reporting, not an open‑market purchase or a cash sale. This is a grant of equity compensation, not a sale, and therefore is generally routine director compensation rather than an investment purchase.

Key Details

• Transaction date: June 8, 2026; Form 4 filed June 10, 2026 (timely filing).
• Reported transaction: 8,150-share option award (derivative), acquisition amount reported as $0.00 (code A).
• Vesting: Shares underlying the award vest monthly in substantially equal 1/12th increments on the last day of each month, beginning June 30, 2026, subject to continued service through each vesting date.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Grant made in connection with Zavrl’s election to the board and issued under the 2025 Equity Incentive Plan per the company’s non-employee director compensation policy.

Context This is a standard equity compensation grant to a newly elected director. The award is a derivative option to purchase shares; the filing does not state the option’s exercise price or whether any vested shares have been or will be sold. Such grants are common as part of director pay and do not, by themselves, signal insider buying or selling activity.